Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer

No abstract is available for this paper.

• Publication year

  2023

• Venue

  British Journal of Cancer

• Publication date

  2023-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41416-023-02219-9PMID 36918717PMCID PMC10147697
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In‐depth proteomic analysis reveals unique subtype‐specific signatures in human small‐cell lung cancer

  2022influential reference
• Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study

  2022cited by this paper
• Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells

  2022cited by this paper
• Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

  2022cited by this paper
• Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.

  2021cited by this paper
• PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses

  2021cited by this paper
• Small-cell lung cancer

  2021cited by this paper
• Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

  2021cited by this paper
• Molecular profiles of small cell lung cancer subtypes: therapeutic implications

  2021cited by this paper
• Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

  2020cited by this paper
• Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization.

  2020cited by this paper
• Immunotherapy in Small Cell Lung Cancer

  2020cited by this paper
• Advances in Small-Cell Lung Cancer (SCLC) Translational Research.

  2020influential reference
• Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

  2020influential reference
• MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression

  2020cited by this paper
• Proteomic Workflows for High-Quality Quantitative Proteome and Post-Translational Modification Analysis of Clinically Relevant Samples from Formalin-Fixed Paraffin-Embedded Archives.

  2020cited by this paper
• Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies

  2020cited by this paper
• BCL2 blockade overcomes MCL1 resistance in multiple myeloma

  2019cited by this paper
• Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

  2019influential reference
• Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma

  2019cited by this paper
• Author contributions

  2019cited by this paper
• Venetoclax: evidence to date and clinical potential

  2019cited by this paper
• BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer

  2018cited by this paper
• Differential role of FL-BID and t-BID during verotoxin-1-induced apoptosis in Burkitt’s lymphoma cells

  2018cited by this paper
• Targeting BCL-2 regulated apoptosis in cancer

  2018cited by this paper
• Managing Patients With Relapsed Small-Cell Lung Cancer.

  2018cited by this paper
• POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

  2018cited by this paper
• ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.

  2018cited by this paper
• Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

  2018influential reference
• Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

  2018cited by this paper
• Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice

  2018cited by this paper
• The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma

  2018cited by this paper
• First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer

  2018cited by this paper
• Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression

  2017cited by this paper
• Small-cell lung cancer: what we know, what we need to know and the path forward

  2017cited by this paper
• BCL-2: Long and winding path from discovery to therapeutic target.

  2017cited by this paper
• Pathways and mechanisms of venetoclax resistance

  2017cited by this paper
• Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia

  2017cited by this paper
• Potential mechanisms of resistance to venetoclax and strategies to circumvent it

  2017cited by this paper
• Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors

  2017cited by this paper
• The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

  2016cited by this paper
• Cellular and molecular biology of small cell lung cancer: an overview.

  2016cited by this paper
• Unraveling the genomic complexity of small cell lung cancer.

  2016cited by this paper
• Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

  2016cited by this paper
• SCLC-State of the Art and What Does the Future Have in Store?

  2016cited by this paper
• Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

  2015cited by this paper
• Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.

  2014cited by this paper
• ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers

  2014cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• BCL2 suppresses PARP1 function and nonapoptotic cell death.

  2012cited by this paper
• Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

  2012cited by this paper
• Reporting : The ARRIVE Guidelines for Reporting Animal Research

  2010cited by this paper
• Tumor Necrosis Factor- (cid:1) Induces Bax-Bak Interaction and Apoptosis, Which Is Inhibited by Adenovirus E1B 19K*

  2001cited by this paper
• Small cell carcinomas of the lung express the Bcl-2 protein.

  1994cited by this paper

• APG-1252 enhances the anticancer role of paclitaxel in non-small-cell lung cancer cells by suppressing the extracellular regulated protein kinases/myeloid cell leukemia 1 pathway.

  2026cites this paper
• Dual-Targeting Bcl-2-Mediated apoptosis and synergistic Pathways: Combinatorial strategies to overcome therapeutic resistance in cancer.

  2026cites this paper
• [The cooperation between three institutions in favor of high-standard thoracic surgical care in the central region of Hungary].

  2025cites this paper
• Small Particles, Big Problems: Polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cells

  2025cites this paper
• TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia

  2025cites this paper
• Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation

  2025cites this paper
• Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives

  2025cites this paper
• The role of Bcl‑2 in controlling the transition between autophagy and apoptosis (Review)

  2025cites this paper
• Immunotherapy for small cell lung cancer: current challenges and prospects

  2025cites this paper
• A multi-omic single-cell landscape reveals transcription and epigenetic regulatory features of t(8;21) AML

  2025cites this paper
• Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer.

  2025cites this paper
• A Chromatography-Guided Co-Fractionation Mass Spectrometry Strategy for Rapid Profiling of Drug-Perturbed Protein Complexes.

  2025cites this paper
• Inhibition of BCL-2 and MCL-1 disrupts mitochondrial respiration and overcomes radioresistance in choroidal melanoma.

  2025cites this paper
• Intratumoral heterogeneity and potential treatment strategies in small cell lung cancer

  2025cites this paper
• GLMP promotes EGFR-TKI resistance by activating autophagy and RhoA pathway in non-small cell lung cancer

  2025cites this paper
• Tangshen formula alleviates doxorubicin induced nephrotoxicity by regulating BAX crosstalk in podocyte.

  2025cites this paper
• Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer

  2025cites this paper
• Advances in biomarkers for immunotherapy in small-cell lung cancer

  2024cites this paper
• Mcl-1 Protein and Viral Infections: A Narrative Review

  2024cites this paper
• Small cells – big issues: biological implications and preclinical advancements in small cell lung cancer

  2024cites this paper
• PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

  2024cites this paper
• Differential synergistic effects of palbociclib and doxorubicin on doxorubicin-resistant cancer cells with diverse tumor origins

  2024cites this paper
• Apoptosis-induced treatment for ovarian cancer from self-assembled nanocomposites of Fe3O4 nanoparticles and porous organic cages

  2024cites this paper
• Capivasertib reverses chemotherapy-induced esophageal cancer resistance via inhibiting Akt-associated Mcl-1 upregulation

  2024cites this paper
• Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer

  2024cites this paper
• Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy.

  2024cites this paper
• A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients

  2024cites this paper
• Strategies to Target Chemoradiotherapy Resistance in Small Cell Lung Cancer

  2024cites this paper
• Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway

  2024cites this paper
• Erianin inhibits the progression of DDP-resistant lung adenocarcinoma by regulating the Wnt/β-catenin pathway and activating the caspase-3 for apoptosis in vitro and in vivo

  2024cites this paper
• Prophylactic cranial irradiation for small cell lung cancer in the era of immunotherapy and molecular subtypes

  2024cites this paper
• Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

  2023cites this paper
• Potential subtype-specific therapeutic approaches in small cell lung cancer

  2023cites this paper
• Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

  2023cites this paper
• Venetoclax Synergizes Sunitinib in Renal Cell Carcincoma through Inhibition of Bcl-2.

  2023cites this paper